XTRA:BAYNPharmaceuticals
Should Kerendia Priority Review in Type 1 Kidney Disease Require Action From Bayer (XTRA:BAYN) Investors?
Earlier this month, Bayer announced that the U.S. FDA accepted a supplemental New Drug Application and granted Priority Review for Kerendia (finerenone) in adults with type 1 diabetes and chronic kidney disease, supported by Phase III FINE-ONE data showing significant reduction in urine albumin-to-creatinine ratio over six months alongside standard care.
This move could broaden Kerendia’s use beyond its existing approvals in chronic kidney disease linked to type 2 diabetes and heart failure...